President Trumps COVID-19 recovery has thrust into the spotlight the possibilities of novel, experimental therapies for this potentially deadly disease. During his stay at Walter Reed National Military Medical Center, he was treated with at least three drugs that have since received substantial attention in the media: the anti-viral remdesivir, the glucocorticoid steroid dexamethasone, and the monoclonal antibody cocktail REGN-COV2.
While evidence suggests these drugs may be effective (and remdesivir just received full marketing approval from the FDA), there are other potential game-changers that have not yet attracted much attention; in fact, almost 2,000 clinical trials of drugs and vaccines (mostly the former) have been registered on the federal governments database. Many of these focus on individuals immune system, either by eliciting an immune response (vaccines) or modulating it, in order that a response is not deleterious.
We Need Vaccines and Therapeutics
While much attention has been paid to the roughlyfive dozen potential vaccine candidatesfor COVID-19 currently in development, even the approval of one or more will not be the end of the COVID-19 pandemic saga. First of all, no vaccine is 100% effective, able to prevent infection, or even symptoms, in all recipients. (The overall average for flu vaccines is 40-60%, while for the first shingles vaccine, it was about 70%).
But as I discussed in a recent article, even an excellent vaccine is no good if no one takes it, and surveys have found significant resistance. A Kaiser Family Foundationpollpublished last month found that only about 42% of Americans would opt for a free COVID-19 vaccination before the presidential election.A similar result emerged from a more recentsurveyby Morning Consult, which found that only 38% would get a coronavirus vaccine if one became available. Those data are in line with the poor uptake of other vaccines intended for adults.
If the poll numbers hold up, even after vaccines are available, we could see continuing high levels of COVID-19 infections, with sporadic surges above baseline. It has been estimated that we will need immunity in roughly70% of the population, through either natural infection or vaccine administration, in order to achieve herd immunity, or community immunity, which occurs when a sufficiently large portion of a community (the herd) becomes immune to a disease that the spread of disease from person to person becomes unlikely.That protects the whole community not just those who are immune.Clearly, we will never even approach that, if a significant fraction of the population rejects the vaccine. Thus, there will be an ongoing need to wear masks, for social distancing, avoidance of crowds indoors, and also for better drug treatments for people who do become infected.
The Immune Response: Too Little or Too Much?
The immune system wanes as people age, resulting in a diminished ability to fight off infections or to mount a vigorous immune response to vaccines hence, the high mortality rate in patients with COVID-19 and the special, higher-dose versions of flu vaccine for seniors. However, in many patients with severe COVID-19, the bodys own exaggerated immune response can be just as damaging if not more so than the virus itself. It can take several forms, including injury to the endothelium (i.e., the cells lining the inside of blood vessels), cytokine storm (the uncontrolled release of proinflammatory proteins, as part of the immune response), or excessive coagulation. These can lead to life-threatening acute respiratory distress syndrome (ARDS) and multi-organ damage. Studies conducted earlier this year showed that the nucleocapsid, or N-protein, of SARS-CoV-2 is involved in activating the lectin pathway, an essential part of the complement system, which provides an organisms effective defense against invading pathogens. The lectin pathway itself is also a proteolytic cascade of molecular events that gives rise to, among other things, the adaptive immune response.
More specifically, a group of Chinese researchers found in studies in mice that the N-proteins of SARS-CoV-2 and other highly pathogenic coronaviruses bind to MASP-2, the key serine protease in the lectin pathway of complement activation, which results in aberrant complement activation and severe inflammatory lung injury. This N-protein-induced complement hyper-activation was also observed in COVID-19 human patients, and a promising suppressive effect was observed when the deteriorating patients were treated with anti-C5a monoclonal antibody. Therefore, they concluded that, Complement suppression may represent a common therapeutic approach for pneumonia induced by these highly pathogenic coronaviruses.
A promising drug candidate that targets this pathway is a monoclonal antibody called narsoplimab that blocks the MASP-2 enzyme and inhibits activation of the lectin pathway. By blocking the activation of this part of the bodys immune system, narsoplimab should dampen the impact of the overactive immune response and prevent a dangerous cascade of complications including coagulation and blood clots, while leaving the anti-infection activity of the adaptive immune response intact.
Narsoplimab is currently being evaluated by the FDA to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and is in Phase 3 clinical trials in IgA nephropathy and atypical hemolytic uremic syndrome. FDA has granted the drug breakthrough therapy designation for both HSCT-TMA and IgA nephropathy. Since injury to endothelial cells (the cells that line blood vessels) is central to the pathophysiology of both COVID-19 infection and HSCT-TMA, the drugs potential to help treat COVID-19 patients is promising. A peer-reviewed studyconducted by Italian and American doctors in Bergamo, Italy an early COVID-19 hotspot suggests that narsoplimab could be an effective treatment for critically ill COVID-19 patients with ARDS and multi-organ disease in patients requiring mechanical ventilation. After two to four weeks of treatment, all six patients in the study recovered and were discharged from the hospital after showing a sustained reduction in all assessed markers of endothelial damage, inflammation, and coagulation. Further, researchers reported no drug-related adverse reactions from any patients in the study and also suggested that two of the patients who had massive bilateral pulmonary thromboses may have benefited from narsoplimabs anticoagulant effects.
Due to the emergent nature of narsoplimabs use in Bergamo, the administration of the drug was not performed as part of a formal, prospective, controlled clinical trial, and the physicians were only able to compare the patients to a control group retrospectively, with the controls showing mortality in excess of 50%. The growing body of literature on the need to stop the cascade of complement activation, coagulation, and inflammation suggests the need for further research on this promising approach to COVID-19, especially in sicker patients in jeopardy of, or experiencing, cytokine storm.
We might, indeed, have to live with COVID-19 infections at some level in the community for the foreseeable future, but it should be with as few hospitalizations and deaths as possible. Therefore, moving forward, the research community should pursue every promising drug and vaccine candidate.
- Doctor: COVID-19 cases will continue to slowly go down, but were not out of the woods - Yahoo Money - January 23rd, 2021
- Global Precision Medicine Market With COVID 19 Impact Analysis| Leading Players In-depth Analysis Research Report Foresight to 2027 - KSU | The... - January 23rd, 2021
- Leading Urologist Doubles Down on CaverStem Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men - PRNewswire - January 22nd, 2021
- Sisters who organised an Ilkley fundraising ball are to be honoured - Wharfedale Observer - January 22nd, 2021
- Medical Doctor: Roes Overlooking of the Consensus of Societal Morality and Science Reverberates to This Day - National Catholic Register - January 22nd, 2021
- DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL)... - January 22nd, 2021
- Seattle researchers find clues for treatments that could eliminate HIV in infected patients - GeekWire - January 14th, 2021
- Flow Cytometry Market is Projected to Reach a Value of US$8100 Mn by the End of 2025 - KSU | The Sentinel Newspaper - January 14th, 2021
- Doctors diagnosed a Suffolk teen with a rare condition. Now, his mom is part of the solution - 13newsnow.com WVEC - January 12th, 2021
- Cassville club assists 2 families as they recover from illness - telegraphherald.com - January 12th, 2021
- The 26 billion-dollar startups to watch that are revolutionizing healthcare in 2021 - Business Insider - January 12th, 2021
- Global Precision Medicine Market 2020 Overview By Size, Share, Trends, Growth Factors and Leading Players With Detailed Analysis of Industry Structure... - January 12th, 2021
- More than 250 articles and a book later, the Valley Doctor bids adieu - San Lorenzo Valley Press-Banner - January 12th, 2021
- Groundbreaking Treatment for Severe COVID-19 Using Stem Cells It's Like Smart Bomb Technology in the Lung - SciTechDaily - January 5th, 2021
- New combo therapy offered against refractory T-cell lymphoma - Korea Biomedical Review - January 5th, 2021
- Hair Growth Treatment Secrets Bollywood Will Never Tell You About - Times of India - January 5th, 2021
- Are metabolic hormones the next frontier in cancer treatment? - MedCity News - January 5th, 2021
- Limerick toddler to wait six months for trial cancer treatment after family raises over 400,000 - Extra.ie - January 5th, 2021
- West Lothian mum fighting for her life after back pain turned out to be terminal blood cancer - Edinburgh Live - January 5th, 2021
- MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab - Yahoo Finance UK - January 5th, 2021
- A Wish Come True urges plungers to dump a bucket of ice water on themselves for this year's fundraiser - Fall River Herald News - December 26th, 2020
- Ashley Cain says over 80,000 people registered for stem cell donation in 48 hours after appeal to save baby - The Sun - December 22nd, 2020
- The 11 most mind-blowing, awe-inspiring health discoveries and innovations of 2020 - Business Insider - Business Insider - December 22nd, 2020
- 3-year-old patient successfully treated for rare fatal disease- familial Hemophagocytic lymphohistiocytosis (HLH) at Fortis Hospital Shalimar Bagh -... - December 22nd, 2020
- Startups are racing to reproduce breast milk in the lab - MIT Technology Review - December 22nd, 2020
- Hand weakness: Causes, symptoms, treatment, and seeking help - Medical News Today - December 22nd, 2020
- Gujarat Issues Health Advisory On Fungal Infection With "50% Mortality Rate" - NDTV - December 22nd, 2020
- A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines - STAT - December 22nd, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - Business Wire - December 9th, 2020
- Medical technologies that will disrupt (and improve) healthcare in the 2020s - Universe.byu.edu - December 9th, 2020
- Community Cord Blood Banking saves life of child with aplastic anaemia - The Hindu - November 20th, 2020
- Arya Lloyd: Father launches global search for blood stem cell donor to save his 12-year-old daughter - Sky News - November 20th, 2020
- Blood Cancer: Science Reveal Five Easily Missed Signs of Leukemia - Science Times - November 20th, 2020
- Karnataka:Community cord blood banking emerges as lifesaver - United News of India - November 18th, 2020
- How CAR-T Cell Therapy is Being Used in the Field of Blood Cancer Treatment - Curetoday.com - November 16th, 2020
- Election results for California Propositions 14, 18, 23, and 24 - FOX 11 Los Angeles - November 16th, 2020
- Cell Separation Beads Market to Witness Robust Expansion Throughout the Forecast Period 2018-2028 - The Daily Philadelphian - November 16th, 2020
- Fight for the rights of unborn - The Daily Telegram - November 11th, 2020
- Genetic Mechanism Identified in Neonatal Diabetes Could Offer Insights into Other Forms of the Disease - Genetic Engineering & Biotechnology News - November 11th, 2020
- Doctors Debate: Is Intensive or Low-Intensity Chemotherapy Plus BCR-ABL TKI Therapy Best for Treatment of Ph+ ALL? - Targeted Oncology - November 11th, 2020
- Record number of stem cell donors apply after Ex On The Beach star plea - expressandstar.com - November 11th, 2020
- Bisbee: A commitment to health care initiatives The Journal Record - Journal Record - November 11th, 2020
- California election results: Where state propositions stand as of Thursday at 5 p.m. - Desert Sun - November 11th, 2020
- Critically ill Indonesian woman thanks Taiwan for saving life - Taiwan News - November 7th, 2020
- City of Hope Doctors Present New Research on Bone Marrow Transplants, Immunotherapy and Other Blood Cancer Treatments - Business Wire - November 7th, 2020
- Daily Edition for Wednesday, November 4, 2020 - California Healthline - November 7th, 2020
- 'We're truly blood brothers' - Stanford coach David Shaw and his recent fight to save his brother, Eric - ESPN - November 7th, 2020
- 'We're really blood brothers' - Stanford coach David Shaw and his current battle to save lots of his brother, Eric - The Shepherd of the Hills Gazette - November 7th, 2020
- Mark Drought: Are we on the brink of another civil war? - The Advocate - November 7th, 2020
- What to eat when you have the flu, recommended by doctors - Business Insider India - October 30th, 2020
- Aborted girl fetus kidneys made Trumps CoV meds. As SARS2 is unfettered in America, this needs thought - Feminine-Perspective Magazine (FPMag) - October 30th, 2020
- What to Know in Washington: Provisional Ballots May Play Role - Bloomberg Government - October 30th, 2020
- Unless the country invests in cancer care, the statistics for breast cancer will be bleak: Dr Anthony Pais, .. - ETHealthworld.com - October 23rd, 2020
- Autologous Fat Grafting Market Scope Analysis 2019 to 2029 - The Think Curiouser - October 23rd, 2020
- How Clinique La Prairie Is Keeping Humanity Fashionably Healthy In The Age Of Covid - Forbes - October 23rd, 2020
- The Anthony Nolan and NHS Stem Cell Registry - The Hippocratic Post - October 21st, 2020
- Jeff Bridges is one of the 85,000-plus lymphoma cases expected in the U.S. this year - MarketWatch - October 21st, 2020
- YOUR HEALTH: Saving an unborn baby breaking apart in the womb - WQAD.com - October 21st, 2020
- Orgenesis completes acquisition of Koligo Therapeutics and announces additional acquisition of Icellator(R) Technology from Tissue Genesis in related... - October 21st, 2020
- SA becomes 2nd country to allow 16 and 17-year-olds to donate bone marrow - News24 - October 21st, 2020
- Stem Cell Therapy Market to Witness Steady Expansion During 2025 KYT24 - KYT24 - October 21st, 2020
- Mohammed Hussain Alqahtani shares his insights about the evolution of plastic surgery - LA Progressive - October 21st, 2020
- Manya Saaraswat Makes Top 5 Finish in 2020 Miss World America Competition, Three Other Indian Americans in Top 10 - India West - October 21st, 2020
- Banking wisdom: Teen saving stem cells in hopes of future treatment - LubbockOnline.com - October 15th, 2020
- Mohammed Hussain Alqahtani Discusses the Future of Plastic Surgery - The Jerusalem Post - October 15th, 2020
- The story of how a biotech co. came to the aid of an ill 9-year-old boy - Stockhouse - October 15th, 2020
- Where Amy Coney Barrett Stands on IVF - Glamour - October 15th, 2020
- Regeneron, Trump, and the alleged hypocrisy of the pro-life movement - Christian Post - October 15th, 2020
- Life Sciences - a year to remember - Lexology - October 15th, 2020
- Proposition 14: With Handful of Cures, Calif. Stem Cell Agency Has Mixed Record. Will Voters Pony Up Another $5.5 Billion? - KQED - October 8th, 2020
- Woman who lost her partner to cancer last year set to run 10K in his memory - Warrington Guardian - October 8th, 2020
- Different Types of Childhood Cancer | INTEGRIS - Integris - October 3rd, 2020
- A perfect match: Bone marrow transplant saves twin brother's life. Now their family pays it forward - 11Alive.com WXIA - October 3rd, 2020
- Baby whose nosebleeds turned out to be deadly condition saved by stranger - Mirror Online - October 3rd, 2020
- Over 40 lakh people in Telangana have developed COVID-19 antibodies: Health Minister Eatala - The New Indian Express - October 3rd, 2020
- Coming of Age: New Research Efforts are Improving Treatment of Childhood Blood Cancers - Curetoday.com - September 23rd, 2020
- World Rose Day 2020: History and significance of the welfare of cancer patients - Hindustan Times - September 23rd, 2020
- Guide to Voting on Propositions and the City of San Bernardino's Measure S - Black Voice News - September 23rd, 2020
- Blood Cancer Awareness Month 2020 - Everyday Health - September 23rd, 2020
- CARLTON FLETCHER: McConnell is the poster boy for sleazy, partisan politics - The Albany Herald - September 23rd, 2020